Daily Endocrinology Research Analysis
Analyzed 103 papers and selected 3 impactful papers.
Summary
Analyzed 103 papers and selected 3 impactful articles.
Selected Articles
1. Letrozole and Infertility Among Males With Spermatogenic Failure: A Randomized Clinical Trial.
In a multicenter randomized, assessor-blinded trial (n=296), letrozole increased the proportion of men with spermatogenic failure who moved to a higher WHO sperm concentration category versus control (14.3% vs 5.4%; P=0.01), with higher odds of achieving better WHO-SCC grades. Letrozole increased gonadotropins and testosterone and lowered estradiol; decreased libido was more frequent but overall tolerability was acceptable.
Impact: Provides randomized evidence supporting an oral, relatively low-cost pharmacologic option to downstage infertility severity in severe spermatogenic failure—an area with scarce high-quality trials.
Clinical Implications: Consider letrozole as an adjunct in men with nonobstructive azoospermia, cryptozoospermia, or severe oligozoospermia to potentially improve sperm concentration category and enable less invasive reproductive strategies; monitor libido and sex steroid changes.
Key Findings
- WHO-SCC upgrade: 14.3% with letrozole vs 5.4% control (risk difference 9.2%, P=0.01).
- Higher odds of better WHO-SCC grade with letrozole (common OR 2.65; P=0.008).
- Serum gonadotropins and testosterone increased, estradiol decreased with letrozole.
- No significant between-group differences in standard semen parameters.
- Decreased libido more frequent with letrozole (12.2% vs 5.4%; P=0.04).
Methodological Strengths
- Multicenter randomized, assessor-blinded design with ITT primary analysis.
- Pre-registered trial with clearly defined categorical primary outcome (WHO-SCC) and hormonal endpoints.
Limitations
- Open-label design may introduce performance bias.
- Short 3-month duration; no live-birth or pregnancy outcomes assessed.
Future Directions: Evaluate longer-term fertility endpoints (e.g., natural conception, ART outcomes), dose-response, and patient-reported sexual function across phenotypes of spermatogenic failure.
IMPORTANCE: Spermatogenic failure (SPGF) is a severe form of male infertility with limited evidence-based medical treatment options. Aromatase inhibitors represent a promising therapeutic strategy for SPGF, but high-quality evidence is lacking. OBJECTIVE: To evaluate the efficacy and safety of letrozole for improving sperm concentration categories in men with SPGF. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, assessor-blinded randomized clinical trial was conducted at 10 male infertility centers in China from July 2023 to March 2024. Men with SPGF (nonobstructive azoospermia [NOA], cryptozoospermia, or severe oligozoospermia) were enrolled. Follow-up for the primary outcome was completed in June 2024. Data were analyzed from July 2024 to March 2025. INTERVENTIONS: Participants were randomized to receive letrozole (2.5 mg daily) plus vitamins C and E or vitamins C and E alone (control group) for 3 months. MAIN OUTCOMES AND MEASURES: The primary outcome was World Health Organization Sperm Concentration Categories (WHO-SCC) upgrade rate at 3 months after randomization. The secondary outcomes were WHO-SCC grades, Dutch Society of Obstetrics and Gynecology Total Motile Sperm Count Categories (NVOG-TMSCC) upgrade rate, semen parameters, and reproductive hormone levels. RESULTS: Among 296 participants (mean [SD] age, 30.2 [3.9] years; 218 [73.6%] with NOA; 147 randomized to the letrozole group and 149 to the control group), 247 (83.4%) completed the trial, and all 296 were included in the primary analysis. WHO-SCC upgrade rates were 14.3% (21 of 147 participants) with letrozole vs 5.4% (8 of 149 participants) with control (risk difference, 9.2% [95% CI, 2.5%-15.8%]; P = .01). Participants in the letrozole group had higher odds of achieving a better WHO-SCC grade than those in the control group (common odds ratio, 2.65 [95% CI, 1.28-5.47]; P = .008). The NVOG-TMSCC upgrade rate was also higher with letrozole. Letrozole significantly increased serum gonadotropins and testosterone while decreasing estradiol. There were no significant between-group differences in semen parameters. Decreased libido (18 [12.2%] vs 8 [5.4%]; P = .04) was more frequent with letrozole than with control. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of men with spermatogenic failure, letrozole significantly improved sperm concentration categories and was well tolerated, supporting its use as an option to downstage infertility severity and potentially enable less invasive reproductive management. TRIAL REGISTRATION: chictr.org.cn Identifier: ChiCTR2300073861.
2. To Cluster or Not to Cluster? A Comparison of Approaches to Targeting Type 2 Diabetes Glucose-Lowering Therapy in the TriMaster Crossover Trial.
In 309 adults who received sitagliptin, canagliflozin, and pioglitazone in a three-way crossover, a routine clinical-features treatment-selection model consistently identified the most effective therapy and yielded greater HbA1c reduction than cluster-based allocation. Polygenic scores and DDRTree-based subgroupings had limited or no utility for predicting within-person differential response.
Impact: Directly compares leading precision-treatment strategies using within-person crossover data, showing that simple, readily available clinical features outperform more complex clustering and genomic approaches for short-term glycemic outcomes.
Clinical Implications: Clinicians can prioritize routine clinical features to guide choice among SGLT2 inhibitors, DPP-4 inhibitors, and TZDs for greater short-term HbA1c reduction, rather than relying on cluster labels or polygenic scores.
Key Findings
- Routine-features model strongly associated with overall and differential HbA1c responses (P<0.0001) and outperformed cluster-based allocation.
- Greater HbA1c reduction with routine-features allocation vs cluster allocation: 0.27% (2.9 mmol/mol) vs 0.16% (1.7 mmol/mol).
- Clinical clusters showed benefit in only one comparison (severe insulin-resistant cluster: SGLT2i > TZD; P=0.005).
- DDRTree-based subgrouping was not associated with treatment response; only 2 of 8 polygenic scores showed modest associations.
Methodological Strengths
- Three-way crossover design with within-person comparisons across three drug classes.
- Head-to-head evaluation of multiple precision approaches using consistent outcomes (HbA1c).
Limitations
- Short-term (4-month per treatment) outcomes; not powered for hard clinical endpoints.
- Models require external validation across broader demographics and care settings.
Future Directions: Prospectively implement the routine-features model in clinical workflows and evaluate long-term outcomes, costs, and scalability across diverse health systems; integrate additional biomarkers only if they add incremental value.
OBJECTIVE: Different precision treatment approaches have been proposed for type 2 diabetes, but robust comparisons are lacking. We compared the utility of proposed approaches targeting glucose-lowering therapy in the TriMaster three-way crossover trial. RESEARCH DESIGN AND METHODS: We evaluated four previously reported precision treatment strategies for their ability to predict overall 4-month HbA1c response and within-person differential response to sitagliptin, canagliflozin, and pioglitazone in 309 adults with type 2 diabetes who received all three medications. Approaches included allocation to clusters based on routine features and HOMA, direct outcome prediction using a routine-features treatment-selection model, type 2 diabetes cluster-specific partitioned polygenic scores (PPSs), and a model based on discriminative dimensionality reduction tree (DDRTree) analysis. RESULTS: The routine-features model and cluster approach were both strongly associated with overall and differential HbA1c responses (P < 0.0001). The routine-features model identified the most effective therapy with significant benefit across all drug comparisons, whereas clinical clusters showed benefit for only one cluster-drug comparison (severe insulin-resistant diabetes: SGLT2i vs. thiazolidinedione [TZD], P = 0.005). DDRTree was not associated with treatment response. Of eight PPSs, only two showed modest association with differential response (lipodystrophy PPS had a greater response to SGLT2 vs. TZD; and β-cell dysfunction, negative proinsulin PPS had a greater response to TZD vs. dipeptidyl peptidase 4 inhibitor). Treatment allocation based on the routine-features model resulted in greater HbA1c reduction than cluster-based allocation (0.27% [95% CI 0.18, 0.35], 2.9 mmol/mol [95% CI 2.0, 3.8] vs. 0.16% [95% CI 0.07, 0.25], 1.7 mmol/mol [95% CI 0.8, 2.7]). CONCLUSIONS: Clinical features are more strongly associated with differential glycemic response than PPS, and direct outcome prediction outperforms data-driven subgrouping for optimizing short-term HbA1c reduction.
3. NIR autofluorescence allows for pituitary gland detection during surgery: evidence from microscopic studies and in vivo measurements.
The authors demonstrated that the pituitary exhibits detectable near-infrared autofluorescence that can be harnessed intraoperatively to distinguish normal gland from PitNETs without exogenous dyes. Microscopic studies and in vivo measurements support the feasibility of label-free, real-time surgical guidance during transsphenoidal procedures.
Impact: Introduces a label-free optical biomarker for intraoperative identification of pituitary tissue, potentially reducing inadvertent gland resection and hypopituitarism—an unmet need in endocrine neurosurgery.
Clinical Implications: If validated, NIR autofluorescence could augment transsphenoidal surgery by enabling real-time discrimination of normal gland from tumor without dyes, informing resection margins and potentially preserving function.
Key Findings
- Pituitary tissue exhibits detectable near-infrared autofluorescence (NIRAF).
- NIRAF can be used intraoperatively for label-free guidance during transsphenoidal surgery.
- Microscopic and in vivo measurements corroborate feasibility for distinguishing normal pituitary from PitNETs.
Methodological Strengths
- Translational approach combining ex vivo/microscopic characterization with in vivo measurements.
- Leverages prior clinical experience with parathyroid NIRAF to inform endocrine surgical application.
Limitations
- Sample size and patient heterogeneity not detailed; early feasibility nature limits generalizability.
- Clinical outcome benefits (e.g., reduced hypopituitarism) not yet demonstrated in controlled trials.
Future Directions: Standardize acquisition/quantification protocols, conduct prospective trials to assess diagnostic accuracy and clinical outcomes, and integrate NIRAF with endoscopic systems.
A critical challenge in endocrine neurosurgery is intraoperative discrimination between normal pituitary tissue and pituitary neuroendocrine tumors (PitNETs). Suggesting the universal persistence of near-infrared autofluorescence (NIRAF) in endocrine organs and inspired by routine clinical use of NIRAF for parathyroid gland identification, we discovered that pituitary NIRAF can be employed for label-free transsphenoidal surgery guidance.